New Approved Drugs Keep Us in the Proverbial Pickle

Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]

“It’s Time to Badger Congress —- Yet Again, Pretty Please!

If you read my previous post ,you will see Senator McCain’s plan to eliminate the Prostate Cancer Research Program within the Congressionally Directed Medical Research Program (CDMRP). The loss of this program could shorten many of our lives and add significantly to our pain and suffering.    Now is the time to work with the rest of [...]

Morbidity and Treatment Regret in Men with Recurrent Prostate Cancer

Researchers wanted to determine if concurrent the development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation) is associated with treatment regret among men with PSA recurrence following failed primary therapy for prostate cancer. The researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, [...]

Changing ADT in the Treatment of Prostate Cancer – Are We Using It Correctly?

Patient advocates have long raised the question about the wisdom in using hormone therapy for extended periods of time. The introduction of intermittent scheduling of hormone therapy (ADT) has become more acceptable thanks to the questions raised by the community and the support of some oncologists who have been willing to think out of the [...]

Life Does Not Come with Do-Overs

Whether you are struggling with advanced prostate cancer, or a member of your family is, we all know how this journey can be very difficult. As we look forward to this New Year, 2011, we can be sure that there will be many difficult and down periods, but we should also remember there will also [...]

Malecare’s Advanced Prostate Cancer Program

Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]

BMI & Prostate Cancer Recurrence

There has been a lot of controversy over the association between obesity and the eventual biochemical failure of men treated for prostate cancer. Research performed at the Cleveland Clinic, Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio attempted to determined whether there is an association between body mass index and biochemical failure [...]

Excessive Alcohol Consumption May Lead to Increased Cancer Risk

The question: Can heavy alcohol consumption accelerate telomere shortening & does telomere shortening cause premature aging and an increased cancer risk? Many of us like to drink alcoholic beverages. I confess, I too enjoy red wind have been known to enjoy a single malt scotch on occasion. However, we always need to remember that excessive [...]

Share Your Comments About the Failure of the White House to Acknowledge Prostate Cancer Awareness Month

I apologize for the lack of posts but I just returned from Virginia where I served as an ad hoc reviewer for U.S. Army Medical Research and Materiel Command (USAMRMC) Prostate Cancer Research Program (PCRP) aka the Congressionally Directed medical Research Program. We spent two very intensive days reviewing prostate cancer research grant applications from [...]

A Take Away Point from the Last American Urological Association (AUA) Meeting

The prognosis of patients with advanced prostate cancer who have lymph node metastasis depends on the number of positive lymph nodes removed and Gleason score of the primary tumor. Bilateral pelvic lymph node dissection should be performed in intermediate- and high-risk patients to identify those with minimal nodal burden who may benefit the most from [...]

Go to Top